Bruker (NASDAQ:BRKR) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

Bruker Corporation (NASDAQ:BRKR) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $39.00 and traded as high as $48.72. Bruker shares last traded at $48.44, with a volume of 1,316,616 shares changing hands.

Wall Street Analyst Weigh In

BRKR has been the subject of several recent research reports. Barclays increased their price objective on Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. TD Cowen boosted their price target on shares of Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a research report on Tuesday, November 4th. Rothschild Redb raised shares of Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Finally, Rothschild & Co Redburn assumed coverage on shares of Bruker in a research note on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus price target of $51.38.

Bruker Price Performance

The firm has a market cap of $7.36 billion, a price-to-earnings ratio of -302.75, a P/E/G ratio of 7.06 and a beta of 1.17. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. The stock’s fifty day moving average price is $44.00 and its 200-day moving average price is $39.00.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities research analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Transactions at Bruker

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd acquired a new position in Bruker during the second quarter worth $192,735,000. AQR Capital Management LLC lifted its stake in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP lifted its stake in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Bruker by 13.9% during the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after acquiring an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. grew its position in Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after acquiring an additional 796,510 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.